Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

104.98 

0.00 0.0%

as of Mar 23 '18 16:00

52 Week Range:

48.28 105.01


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States, Japan, and internationally. The company offers ELOCTATE, an antihemophilic factor Fc fusion protein; and ALPROLIX, a coagulation factor IX Fc fusion protein for the treatment of hemophilia A and B. It is also developing BIVV001, a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV002, a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A, as well as gene therapy program, a preclinical program to develop gene therapies for hemophilia A and B. Bioverativ has collaboration with Swedish Orphan Biovitrum AB (publ) to develop and commercialize ELOCTATE and ALPROLIX worldwide; and a research collaboration agreement with Bicycle Therapeutics Ltd. for the discovery, development, and commercialization of therapies for haemophilia and sickle cell diseases. Bioverativ Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. As of March 7, 2018, Bioverativ Inc. operates as a subsidiary of Sanofi.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 6.93
growth rate
Earnings BIT 98.00
292.40
growth rate 198.4%
Avg.PE 13.38
25.11
growth rate 87.7%
ROA -95.72
14.46
72.81
30.26
growth rate 100.0% 403.5% -58.4%
ROE -122.63
18.16
92.46
48.59
growth rate 100.0% 409.1% -47.5%
ROIC -122.63
18.16
92.46
48.59
growth rate 100.0% 409.1% -47.5%
Cur. Ratio 3.80
5.82
4.66
2.00
growth rate 53.2% -19.9% -57.1%
Quick Ratio 1.02
1.57
1.46
1.60
growth rate 53.9% -7.0% 9.6%
Leverage 1.28
1.24
1.29
1.80
growth rate -3.1% 4.0% 39.5%
Balance Sheet Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 94.40
149.40
growth rate 58.3%
Acct.Payable 10.80
12.70
growth rate 17.6%
Cur.Assets 350.50
475.60
growth rate 35.7%
Total Assets 475.60
731.90
growth rate 53.9%
Cash 0.00 0.00
growth rate
Inventory 252.10
302.00
growth rate 19.8%
Cur.Liabilities 60.20
102.00
growth rate 69.4%
Liabilities 90.90
165.70
growth rate 82.3%
LT Debt 0.00 0.00
growth rate
Equity 384.70
566.20
growth rate 47.2%
Common Shares 108.00
110.00
108.00
109.00
growth rate 1.9% -1.8% 0.9%
Cash Flow Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Cash Dividends 0.00 0.00
growth rate
Cash From OA 41.40
301.60
growth rate 628.5%
FCF per Share 3.97
growth rate
Sale Purchase of Stock 0.00 0.00
growth rate
FCF -438.00
-513.00
30.80
266.40
577.60
growth rate 0.0% 100.0% 764.9% 116.8%
Income Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 560.30
887.40
growth rate 58.4%
Op.Income 108.60
439.60
growth rate 304.8%
IBT 98.00
292.40
growth rate 198.4%
Net Income 108.60
439.60
growth rate 304.8%
EPS -3.34
0.56
4.07
3.28
growth rate 100.0% 626.8% -19.4%
Gross Profit 507.40
649.50
growth rate 28.0%
R&D 186.10
178.80
growth rate -3.9%

Quarterly Statements

Item Name Sep '16 Dec '16 Mar '17 Jun '17
Balance Sheet
Acct.Receivable 126.80
149.40
144.40
179.00
growth rate 17.8% -3.4% 24.0%
Acct.Payable 12.30
12.70
16.00
17.20
growth rate 3.3% 26.0% 7.5%
Cur.Assets 420.40
475.60
678.70
465.70
growth rate 13.1% 42.7% -31.4%
Total Assets 540.90
731.90
796.60
1,357.50
growth rate 35.3% 8.8% 70.4%
Cash 0.00
0.00
358.70
137.40
growth rate -61.7%
Inventory 283.30
302.00
91.40
50.00
growth rate 6.6% -69.7% -45.3%
Cur.Liabilities 81.20
102.00
138.40
230.30
growth rate 25.6% 35.7% 66.4%
Liabilities 135.00
165.70
211.50
685.30
growth rate 22.7% 27.6% 224.0%
LT Debt 0.00 0.00 0.00 0.00
growth rate
Equity 405.90
566.20
585.10
672.20
growth rate 39.5% 3.3% 14.9%
Cash Flow Statement Sep '16 Dec '16 Mar '17 Jun '17
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA 76.10
68.30
108.20
133.20
growth rate -10.3% 58.4% 23.1%
Sale Purchase of Stock 0.00 0.00 0.00 0.00
growth rate
Income Statement Sep '16 Dec '16 Mar '17 Jun '17
Sales 229.20
256.20
259.10
289.10
growth rate 11.8% 1.1% 11.6%
Op.Income 80.50
228.90
69.30
77.10
growth rate 184.4% -69.7% 11.3%
IBT 79.20
84.40
111.90
113.60
growth rate 6.6% 32.6% 1.5%
Net Income 80.50
228.90
69.30
77.10
growth rate 184.4% -69.7% 11.3%
Gross Profit 157.60
180.50
195.80
208.60
growth rate 14.5% 8.5% 6.5%
R&D 35.00
56.20
36.90
33.70
growth rate 60.6% -34.3% -8.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (62.23)

YOY Growth Grade:

C (59.01)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 32.01 32.01 23.07
EPS / Growth 3.28 9.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 47.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 9.0% 28.1% 28.1%
Future PE 18.00 37.09 37.09
Future EPS 7.77 39.00 39.00
Value Price
MOS %
34.55
-67.1%
357.50
240.5%
357.50
240.5%
MOS Price 17.27 178.75 178.75
IRT 15.00 8.38 8.38

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.